BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-50@pharmaconomics
DTSTAMP:20260707T034740Z
DTSTART;VALUE=DATE:20261106
DTEND;VALUE=DATE:20261107
SUMMARY:NVS Phase 3 — LOU064 (blinded)
DESCRIPTION:Phase 3 trial results for LOU064 (blinded) in Chronic Spontaneous Urticaria are due Nov 6\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT05677451\n\nTrack it: https://www.pharmaconomics.com/e/50
URL:https://www.pharmaconomics.com/e/50
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:NVS catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR